CTLA4 and lung cancer: Immunotherapy has brought up new options for lung cancer patients, including blockade of immune checkpoints like cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death 1 (PD-1) [3, 4].